Technology
Health
Pharmaceutical

Kiniksa Pharmaceuticals

$14.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.30 (2.17%) As of 3:05 PM EDT today
+$0.30 (2.17%) Today

Why Robinhood?

You can buy or sell KNSA and other stocks, options, ETFs, and crypto commission-free!

About KNSA

Kiniksa Pharmaceuticals, Ltd. Class A Common Stock, also called Kiniksa Pharmaceuticals, is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Read More Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

Employees
111
Headquarters
Hamilton, Hamilton
Founded
2015
Market Cap
751.48M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
118.79K
High Today
$14.50
Low Today
$13.79
Open Price
$13.90
Volume
35.91K
52 Week High
$32.88
52 Week Low
$13.04

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Medical
2018 IPO
North America (Non-US/Canada)
North America

KNSA Earnings

-$1.27
-$0.99
-$0.72
-$0.44
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 5, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.